Answers are grounded in this paper and cite their sources.
Background Melasma is a chronic, acquired hyperpigmentation disorder that predominantly affects reproductive-aged women, with prevalence reaching 9%–50% in high-risk populations; local adverse reactions and modest sustained efficacy limit conventional therapies. Acupoint thread embedding (ATE), a technique that provides sustained acupoint stimulation, has shown preliminary promise; however, no updated systematic review has synthesized the accumulating evidence. Methods We searched nine bibliographic databases (PubMed, Embase, Cochrane Library, Web of Science, Scopus, CNKI, Wanfang, VIP, and CBM) and two trial registries (ClinicalTrials.gov and ICTRP) from inception to June 2026 for randomized controlled trials (RCTs) evaluating ATE for melasma. The primary outcome was the total effective rate; secondary outcomes included Melasma Area and Severity Index (MASI) scores, recurrence, and adverse events (AEs). Risk of bias was assessed using RoB 2, and evidence certainty was evaluated using GRADE. Random-effects models were used for meta-analysis. Results Nineteen RCTs involving 1,539 patients were included; 18 contributed to meta-analysis, and all were at high risk of bias. In the primary add-on analysis (ATE plus co-intervention vs. the same co-intervention alone; n = 9), ATE increased the total effective rate [risk ratio [RR] = 1.24, 95% confidence interval [CI]: 1.16–1.33; I 2 = 0%]. Pooling all comparison designs ( n = 18) yielded an RR of 1.24 (95% CI: 1.17–1.31; I 2 = 22%), potentially overestimating the incremental effect of ATE. For MASI scores, the pooled mean difference (MD), calculated as the pretreatment score minus the post-treatment score, was 2.81 (95% CI: 0.02–5.61; I 2 = 94%), favoring ATE; however, substantial heterogeneity rendered this finding exploratory. Recurrence showed a nonsignificant trend favoring ATE (RR = 0.53, 95% CI: 0.25–1.12; n = 2). Reported AEs were mainly mild and transient. No serious AEs were reported in studies providing safety data, but incomplete reporting precluded reliable safety assessment. Conclusion ATE combined with co-interventions may improve the total effective rate and MASI scores in patients with melasma. However, the certainty of evidence was very low, and the MASI findings were highly heterogeneous and exploratory. Rigorous, high-quality RCTs are needed to establish its efficacy and safety. Registration PROSPERO (CRD420261427231; https://www.crd.york.ac.uk/PROSPERO/recorddashboard ).
No takes yet. Share an insight, caveat, or question.
Guo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: